Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency the IRONOUT HF randomized clinical trial

JAMA - Journal of the American Medical Association

Volumn 317, Issue 19, 2017, Pages 1958-1966

  Lewis, Gregory D ^a   Malhotra, Rajeev ^a   Hernandez, Adrian F ^b   McNulty, Steven E ^b   Smith, Andrew ^c   Michael Felker, G ^d   Wilson Tang, W H ^e   LaRue, Shane J ^f   Redfield, Margaret M ^g   Semigran, Marc J ^a   Givertz, Michael M ^h   Van Buren, Peter ⁱ   Whellan, David ^j   Anstrom, Kevin J ^b   Shah, Monica R ^k   Desvigne Nickens, Patrice ^k   Butler, Javed ^l   Braunwald, Eugene ^h  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^c EMORY UNIVERSITY   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ UNIVERSITY OF VERMONT   (United States)

^j THOMAS JEFFERSON UNIVERSITY   (United States)

^k NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^l STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; FERRITIN; IRON POLYSACCHARIDE; PLACEBO; BRAIN NATRIURETIC PEPTIDE; IRON; IRON DERIVATIVE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76); TRANSFERRIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG WITHDRAWAL; EXERCISE; FEMALE; FERRITIN BLOOD LEVEL; HEALTH STATUS; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; IRON DEFICIENCY; IRON THERAPY; KANSAS CITY CARDIOMYOPATHY QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; OXYGEN CONSUMPTION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SIX MINUTE WALK TEST; UNSPECIFIED SIDE EFFECT; BLOOD; CLINICAL TRIAL; COMPLICATION; DEFICIENCY; EXERCISE TOLERANCE; HEART STROKE VOLUME; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; WALK TEST;

ADMINISTRATION, ORAL; AGED; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; FERRITINS; HEALTH STATUS; HEART FAILURE; HUMANS; IRON; IRON COMPOUNDS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; OXYGEN CONSUMPTION; PEPTIDE FRAGMENTS; QUALITY OF LIFE; STROKE VOLUME; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME; WALK TEST;

EID: 85019870889     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.5427     Document Type: Article

References (31)

1. Pasricha SR. Anemia: a comprehensive global estimate. Blood. 2014;123(5):611-612.
2. Klip IT, Comin-Colet J, Voors AA, et al Iron deficiency in chronic heart failure. Am Heart J. 2013; 165(4):575-582.e573.
3. Jankowska EA, Rozentryt P, Witkowska A, et al. Iron deficiency predicts impaired exercise capacity in patients with systolic chronic heart failure. J Card Fail. 2011;17(11):899-906.
4. Weiss G, Goodnough LT. Anemiaof chronic disease. N Engl J Med. 2005;352(10):1011-1023.
5. Dong F, Zhang X, Culver B, Chew HG Jr, Kelley RO, Ren J. Dietary iron deficiency induces ventricular dilation, mitochondrial ultrastructural aberrations and cytochrome c release. Clin Sci (Lond). 2005;109(3):277-286.
6. Toblli JE, Lombraña A, Duarte P, Di Gennaro F. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency. J Am Coll Cardiol. 2007;50(17):1657-1665.
7. Dunn LL, Suryo Rahmanto Y, Richardson DR. Iron uptake and metabolism in the new millennium. Trends Cell Biol. 2007;17(2):93-100.
8. Haas JD, Brownlie T 4th. Iron deficiency and reduced work capacity. J Nutr. 2001;131(2S-2):676S-688S; discussion 688S-690S.
9. Andrews NC. Disorders of iron metabolism. N Engl J Med. 1999;341(26):1986-1995.
10. Melenovsky V, Petrak J, Mracek T, et al. Myocardial iron content and mitochondrial function in human heart failure. Eur J Heart Fail. 2017;19(4): 522-530.
11. Georgieva Z, Georgieva M. Compensatory and adaptive changes in microcirculation and left ventricular function of patients with chronic iron-deficiency anaemia. Clin Hemorheol Microcirc. 1997;17(1):21-30.
12. Jankowska EA, Ponikowski P. Molecular changesin myocardiumin the course of anemia or iron deficiency. Heart Fail Clin. 2010;6(3):295-304.
13. Anker SD, Comin Colet J, Filippatos G, et al; FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361(25):2436-2448.
14. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, et al; CONFIRM-HF Investigators. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J. 2015;36(11): 657-668.
15. Lewis GD, Semigran MJ, Givertz MM, et al. Oral iron therapy for heart failure with reduced ejection fraction: design and rationale for oral iron repletion effects on oxygen uptake in heart failure. Circ Heart Fail. 2016;9(5):e000345.
16. Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluationofthe Kansas City Cardiomyopathy Questionnaire. J Am Coll Cardiol. 2000;35(5):1245-1255.
17. 2 response time in systolic heart failure. Circ Heart Fail. 2013;6(3):499-507.
18. Nemeth E, Valore EV, Territo M, Schiller G, Lichtenstein A, Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood. 2003;101(7):2461-2463.
19. Nicolas G, Chauvet C, Viatte L, et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J Clin Invest. 2002;110(7):1037-1044.
20. Ganz T. Hepcidin and iron regulation, 10 years later. Blood. 2011;117(17):4425-4433.
21. Nemeth E, Tuttle MS, Powelson J, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science. 2004;306(5704):2090-2093.
22. Franchini M, Montagnana M, Lippi G. Hepcidin and iron metabolism. Clin Chim Acta. 2010;411(21-22):1565-1569.
23. 2 is related to better clinical outcomes in chronic heart failure patients. Circ Heart Fail. 2012;5(5):579-585.
24. Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. JACC Heart Fail. 2016;4(8):607-616.
25. Okonko DO, Grzeslo A, Witkowski T, et al. Effect of intravenous iron suc6829287rose on exercise tolerance in anemic and nonanemic patients with symptomatic chronic heart failure and iron deficiency FERRIC-HF. J Am Coll Cardiol. 2008;51(2):103-112.
26. Beck-da-Silva L, Piardi D, Soder S, et al. IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol. 2013;168(4):3439-3442.
27. van Santen S, van Dongen-Lases EC, de Vegt F, et al. Hepcidin and hemoglobin content parameters in the diagnosis of iron deficiency in rheumatoid arthritis patients with anemia. Arthritis Rheum. 2011;63(12):3672-3680.
28. Choi HS, Song SH, Lee JH, Kim HJ, Yang HR. Serum hepcidin levels and iron parameters in children with iron deficiency. Korean J Hematol. 2012;47(4):286-292.
29. Jacobs P, Fransman D, Coghlan P. Comparative bioavailability of ferric polymaltose and ferrous sulphate in iron-deficient blood donors. J Clin Apher. 1993;8(2):89-95.
30. Wingard RL, Parker RA, Ismail N, Hakim RM. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis. 1995;25(3):433-439.
31. Glassman E. Oral iron therapy with ferrous fumarate and polysaccharide iron complex. ANNA J. 1992;19(3):277-278, 323.